Department of Molecular and Translational Medicine, Viale Europa, 11, University of Brescia, Brescia 25123, Italy Humanitas Clinical and Research Center, Rozzano, Italy
Department of Molecular and Translational Medicine, Viale Europa, 11, University of Brescia, Brescia 25123, Italy Humanitas Clinical and Research Center, Rozzano, Italy.
Cardiovasc Res. 2015 Aug 1;107(3):364-72. doi: 10.1093/cvr/cvv150. Epub 2015 May 12.
Chemokines are key mediators of inflammation. In pathological tissues, the main roles of chemokines are to regulate leucocyte accumulation through the activation of oriented cell migration and the activation of limited programs of gene transcription. Through these activities, chemokines exert many crucial functions, including the regulation of angiogenesis. The 'chemokine system' is tightly regulated at several levels, such as the post-transcriptional processing of ligands, the regulation of the expression and function of the receptors and through the expression of molecules known as 'atypical chemokine receptors', proteins that function as chemokine scavenging and presenting molecules. Several experimental evidence obtained in vitro, in animal models and in human studies, has defined a crucial role of chemokines in cardiovascular diseases. An intense area of research is currently exploring the possibility to develop new effective therapeutic strategies through the identification of chemokine receptor antagonists.
趋化因子是炎症的关键介质。在病理组织中,趋化因子的主要作用是通过激活定向细胞迁移和激活有限的基因转录程序来调节白细胞的积累。通过这些活动,趋化因子发挥了许多关键功能,包括调节血管生成。“趋化因子系统”在多个水平上受到严格调节,例如配体的转录后加工、受体的表达和功能的调节以及通过表达被称为“非典型趋化因子受体”的分子,这些蛋白质作为趋化因子清除和呈递分子发挥作用。在体外、动物模型和人类研究中获得的几项实验证据已经确定了趋化因子在心血管疾病中的关键作用。目前,一个研究热点领域正在探索通过鉴定趋化因子受体拮抗剂来开发新的有效治疗策略的可能性。